Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum ...

The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail. The lower, 50 milligram twice-daily dose in that successful study ...

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why ...

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s ...

Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, ...

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major ...